Financial Review: Metagenomi (MGX) versus Its Peers

Metagenomi (NASDAQ:MGX) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Metagenomi to similar companies based on the strength of its earnings, profitability, dividends, risk, analyst recommendations, institutional ownership and valuation.

Valuation and Earnings

This table compares Metagenomi and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Metagenomi	$52.30 million	-$68.25 million	-0.60
Metagenomi Competitors	$575.37 million	-$70.96 million	-1.97

Metagenomi’s peers have higher revenue, but lower earnings than Metagenomi. Metagenomi is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Metagenomi has a beta of -0.65, indicating that its stock price is 165% less volatile than the S&P 500. Comparatively, Metagenomi’s peers have a beta of -4.50, indicating that their average stock price is 550% less volatile than the S&P 500.

Profitability

This table compares Metagenomi and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Metagenomi	-134.27%	-43.23%	-18.86%
Metagenomi Competitors	-2,185.76%	-161.46%	-40.62%

Insider & Institutional Ownership

50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.6% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Metagenomi and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	0	0	4	0	3.00
Metagenomi Competitors	1980	5478	14091	306	2.58

Metagenomi currently has a consensus price target of $14.75, indicating a potential upside of 839.49%. As a group, “Biological products, except diagnostic” companies have a potential upside of 115.35%. Given Metagenomi’s stronger consensus rating and higher possible upside, analysts clearly believe Metagenomi is more favorable than its peers.

Summary

Metagenomi beats its peers on 9 of the 13 factors compared.

About Metagenomi

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.